Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

Journal of Clinical Pharmacology

Volumn 49, Issue 11, 2009, Pages 1297-1308

  Chapel, Sunny ^a,d   Hutmacher, Matt M ^a,d   Haig, George ^a   Bockbrader, Howard ^a,e   De Greef, Rik ^b   Preskorn, Sheldon H ^c   Lalonde, Richard L ^a,e  

^a PFIZER INC   (United States)

^b Pharmacokinetics Pharmacodynamics and Pharmacometrics   (Netherlands)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^d ANN ARBOR PHARMACOMETRICS GROUP   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Asenapine; E R analysis; Qtc prolongation; Schizophrenia

Indexed keywords

ASENAPINE; PLACEBO; QUETIAPINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; ELECTROCARDIOGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; LINEAR MODELS; LONG QT SYNDROME; MALE; MIDDLE AGED; SCHIZOPHRENIA; TIME FACTORS;

EID: 70350424361     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009344855     Document Type: Article

References (18)

1. Hanton G., Tilbury L. Cardiac safety strategies. 25-26 October 2005, the Radisson SAS Hotel, Nice, France. Expert Opin Drug Saf. 2006 ; 5: 329-333.
2. Taylor DM Prolongation of QTc interval and antipsychotics. Am J Psychiatry. 2002 ; 159: 1062.
3. Shah RR Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf. 2005 ; 28: 1009-1028.
4. Shah RR Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf. 2005 ; 28: 115-125.
5. Shahid M., Walker GB, Zorn SH, Wong EH Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 ; 23 (1). 65-73.
6. Potkin SG, Cohen M., Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidonecontrolled trial. J Clin Psychiatry. 2007 ; 68: 1492-1500.
7. McIntyre R., Hirschfeld R., Calabrese J., Panagides J. Asenapine in bipolar disorder: an overview of clinical trials in the Olympia program. Paper presented at: American Psychiatric Association 161st Annual Meeting; May 3-8, 2008 ; Washington, DC.
8. Cutler NR Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychiatry. 2001 ; 62 (suppl 5). 10-13.
9. International Conference on Harmonisation. Guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist. 2005 ; 70: 61134-61135.
10. Harrigan EP, Miceli JJ, Anziano R., et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004 ; 24: 62-69.
11. Hutmacher MM, Chapel S., Agin MA, Fleishaker JC, Lalonde RL Performance characteristics for some typical QT study designs under the ICH E-14 guidance. J Clin Pharmacol. 2008 ; 48: 215-224.
12. Yano Y., Beal SL, Sheiner LB Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001 ; 28: 171-192.
13. Davis JD, Hackman F., Layton G., Higgins T., Sudworth D., Weissgerber G. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol. 2008 ; 65 (suppl 1). 68-75.
14. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 ; 158: 1774-1782.
15. Lindstrom E., Farde L., Eberhard J., Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol. 2005 ; 8: 615-629.
16. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs. 2003 ; 17: 423-430.
17. Krebs M., Leopold K., Hinzpeter A., Schaefer M. Current schizophrenia drugs: efficacy and side effects. Expert Opin Pharmacother. 2006 ; 7: 1005-1016.
18. Sharma ND, Rosman HS, Padhi ID, Tisdale JE Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998 ; 81: 238-240.